Terumo (TRUMY) Projected to Post Earnings on Friday

Key Points

• Upcoming earnings (May 15): Terumo is expected to report quarterly results on Friday, May 15, with analysts forecasting $0.11 EPS and $1.84 billion in revenue.
• In the prior quarter Terumo reported $0.14 EPS (missing the $0.15 consensus) while beating revenue expectations with $1.94 billion versus $1.82 billion, and analysts project about $1.00 EPS for both the current and next fiscal year.
• Shares trade near $12.31 with a 12‑month range of $12.15–$20.12, a market cap of about $18.16 billion and a P/E of 21.22, and the stock carries an average Wall Street rating of Hold.

Terumo (OTCMKTS:TRUMY - Get Free Report) is anticipated to release its resultson Friday, May 15th. Analysts expect Terumo to post earnings of $0.11 per share and revenue of $1.84 billion for the quarter.

Terumo (OTCMKTS:TRUMY - Get Free Report) last posted its earnings results on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Terumo had a net margin of 11.74% and a return on equity of 9.01%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.82 billion. On average, analysts expect Terumo to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Terumo Stock Performance

Terumo stock opened at $12.31 on Friday. The company's 50-day moving average price is $13.15 and its 200-day moving average price is $14.17. Terumo has a twelve month low of $12.15 and a twelve month high of $20.12. The company has a quick ratio of 0.89, a current ratio of 1.51 and a debt-to-equity ratio of 0.07. The company has a market cap of $18.16 billion, a PE ratio of 21.22 and a beta of 0.62.

Wall Street Analyst Weigh In

Several research analysts recently commented on TRUMY shares. Nomura upgraded Terumo to a "hold" rating in a research report on Tuesday, February 24th. Zacks Research raised Terumo to a "hold" rating in a research note on Thursday, April 9th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of "Hold".

Terumo Company Profile

Terumo Corporation OTCMKTS: TRUMY is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.